What is GEHC's intrinsic value?

TickerWorth's valuation lenses put GE HealthCare Technologies Inc. (GEHC) between $40.09 and $127.43 per share, versus a market price of $69.57. They disagree too widely for us to state a single fair value, so we publish the range.

Is GEHC overvalued or undervalued?

At $69.57 the price sits inside a range too wide to call either way. We don't call GEHC overvalued or undervalued from a range this wide. This is an educational estimate, not advice.

What discount rate is used for GEHC?

A WACC of 8.3% and a terminal growth rate of 2.5%.

Is GE HealthCare Technologies stock undervalued?

TickerWorth's fair-value range for GE HealthCare Technologies Inc. (GEHC) is $40.09 – $127.43 against a market price of $69.57. Too wide to call. We publish a range here, not one number, so we do not call it over- or undervalued. This is a model estimate, not investment advice.

GE HealthCare Technologies (GEHC) DCF valuation and fair value

Our fair-value range for GE HealthCare Technologies Inc. (GEHC) is $40.09 – $127.43, built on a 8.3% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.

What growth is priced into GE HealthCare Technologies stock?

Today's price implies revenue growth of 4.5% a year for 5 years; our model assumes 4.3% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $69.57. A model estimate, not investment advice.

GE HealthCare Technologies (GEHC) insider trading

The most recent insider filing (SEC Form 4) for GE HealthCare Technologies Inc. (GEHC): Grogan William K, Chief Financial Officer, grant / award on 2026-09-14. The latest filings are listed on this page. A disclosure, not a signal to trade.

GEHC · Intrinsic value

Is GE HealthCare Technologies Inc. (GEHC) overvalued or undervalued?

Name: GE HealthCare Technologies Inc. (GEHC) DCF intrinsic value
Creator: TickerWorth

As of Oct 19, 2026, TickerWorth's valuation lenses put GE HealthCare Technologies Inc. (GEHC) at $40.09 – $127.43, too broad a range to say where the delayed market price of $69.57 sits in it, so we do not call it over- or undervalued. It is a model estimate, and every input behind it is sourced below.

Model by Miraaj Patel · generated from a hand-researched model · Updated Oct 19, 2026 · How these pages are made

Open full GEHC analysis

What is GEHC worth?

Fair-value range: $40.09 – $127.43
Market price: $69.57
Gap to fair value: —
Verdict: Too wide to call

Price as of 19 Oct 2026, 13:16 UTC · Prices are delayed.Our valuation lenses disagree too widely on this company for us to publish a single number, so we publish the range instead. We do not call it over- or undervalued from a spread this wide.

Fair-value range against the delayed market price: Too wide to call.

Reverse DCF: Today's price implies revenue growth of 4.5% a year for 5 years; our model assumes 4.3% a year on average over the same horizon.

What is GEHC's TickerWorth Score?

C54/100

Middle of the pack — real strengths and real weaknesses

Compared with Healthcare companies in US

Its strongest point: looks cheap on the numbers. Its weakest: balance sheet looks stretched.

Value · 78 of 100
Cheaper than 78% of Healthcare companies in US
Price vs worth · 64 of 100
Quality · 55 of 100
More profitable than 55% of Healthcare companies in US
Financial health · 29 of 100
Financially stronger than 29% of Healthcare companies in US
Growth · 40 of 100
Growing faster than 40% of Healthcare companies in US
Momentum · 36 of 100
Outperformed 36% of Healthcare companies in US over the past year

Confidence: Medium confidence · Scored 19 Oct 2026, 13:16 UTC

Get the Undervalued Company of the Week.

Where the numbers come from

Hand-researched model

What the modeller flagged

YEAR-1 FCF IS ~35% ABOVE REPORTED FCF ($2.03B modelled unlevered vs $1,505M reported for FY2025; FY2026 guidance ~$1.6B) — past the 20% line, so stated. It decomposes: reported FCF is after ~$410M of after-tax cash interest (the model is unlevered; debt sits in net debt) and ~$270M of after-tax pension/OPEB contributions (the deficit sits in net debt instead), and FY2025 also carried ~$285M of tariff cash. Strip those out of $1.5-1.6B and you land near $2.0-2.2B.
TERMINAL VALUE IS ~78% OF ENTERPRISE VALUE — above the 75% line. Only ~22% of the answer comes from the five forecast years; the value is a bet on GEHC holding a ~14.8% GAAP operating margin indefinitely.
THE MARGIN RECOVERY IS THE SOFTEST INPUT AND IT PUSHES THE VALUE UP. GEHC's GAAP operating margin was 12.5% (FY2023), 13.3% (FY2024) and 13.4% (FY2025); the model reaches 14.8% by 2030. Holding 13.1% flat for all five years would take the value down to about $54. Even Y1 needs a much stronger H2 2026 (implied ~17% adjusted margin vs 13.8% in H1).
ADJUSTED vs GAAP: a model run on management's Adjusted EBIT (15.5% in 2026, rising to ~17.3%) instead of GAAP operating income would land ~$17/share higher. The difference is restructuring that recurs every year, acquisition costs and acquired-intangible amortization from a company that keeps acquiring — treated here as real costs.
PENSION FIGURE IS A YEAR-END MEASUREMENT (2025-12-31); pension plans are remeasured annually, so the 10-Qs carry no update. Higher discount rates since year-end probably shrank the deficit; GEHC's liability-hedging program dampens that sensitivity.
SBC of $130M (FY2025, 0.6% of revenue) is expensed inside GAAP operating income and not added back; dilution is captured by the weighted-diluted share count.

Why GEHC gets a range, not one number

At a recent price of $69.57, GE HealthCare Technologies Inc. (GEHC) sits inside a range too wide to call either way: our valuation lenses put the business somewhere between $40.09 and $127.43 per share. They disagree too widely for us to state a single fair value. We publish the range rather than a midpoint because a number that precise would claim more than the methods can support. This is an educational model, not a price target or a recommendation.

Read the full reasoning

The valuation discounts GE HealthCare Technologies Inc.'s projected free cash flows at a weighted-average cost of capital (WACC) of 8.3%, with a long-run terminal growth rate of 2.5%. About 78% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.

Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly 4.5% annual revenue growth for GEHC. Our base case instead compounds to about 4.3% a year over the same forecast, so the market's implied growth is broadly in line with our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.

Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, GEHC's modeled DCF value ranges from about $38.21 to $130.74 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.

How to read this page: the DCF fair value is what GE HealthCare Technologies Inc. would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of GEHC's intrinsic value. Figures update as new filings and prices come in.

Every input behind GEHC's DCF

Input	Value	Source
Base-year revenueGE HealthCare 4Q/FY2025 earnings release, 8-K Ex-99 (accession 0001932393-26-000006, filed 2026-02-04); FY2025 10-K (accession 0001932393-26-000007): Total revenues FY2025 $20,625M, +4.8% on FY2024's $19,672M (organic +3.5%; the rest is FX and the Nihon Medi-Physics and icometrix acquisitions). CROSS-CHECK, H1 2026 (Q2 release, accession 0001932393-26-000045): revenue $10,425M, +6.6% reported and +3.2% organic, with $205M of FX tailwind and ~$122M from acquisitions (mainly Intelerad, closed 2026-03-18). Calendar fiscal year, so FY2025 is the latest completed year with a filed 10-K.	$20,625,000,000	GE HealthCare 4Q/FY2025 earnings release, 8-K Ex-99 (accession 0001932393-26-000006, filed 2026-02-04); FY2025 10-K (accession 0001932393-26-000007): Total revenues FY2025 $20,625M, +4.8% on FY2024's $19,672M (organic +3.5%; the rest is FX and the Nihon Medi-Physics and icometrix acquisitions). CROSS-CHECK, H1 2026 (Q2 release, accession 0001932393-26-000045): revenue $10,425M, +6.6% reported and +3.2% organic, with $205M of FX tailwind and ~$122M from acquisitions (mainly Intelerad, closed 2026-03-18). Calendar fiscal year, so FY2025 is the latest completed year with a filed 10-K.
Base EBIT marginGE HealthCare 4Q/FY2025 earnings release, 8-K Ex-99 (accession 0001932393-26-000006): GAAP OPERATING INCOME, not the company's 'Adjusted EBIT'. FY2025 operating income $2,763M / revenue $20,625M = 13.40%. This line is BEFORE non-operating pension income ($288M in FY2025, a non-cash expected-return credit, deliberately excluded because the pension deficit is carried in net debt instead) and before 'other income' ($157M, of which $112M was investment revaluation gains). It INCLUDES and keeps as real costs: restructuring $120M (it has been $120M in each of the last two years — recurring, not one-off), acquisition charges $39M, spin-off costs $38M (now ~zero; leaving them in costs ~0.2pt in the base only), the ~$245M tariff hit, and $156M of acquired-intangible amortization. Management's Adjusted EBIT margin for the same year was 15.3% ($3,155M) — the ~1.9pt gap is exactly those add-backs plus the other-income line. CROSS-CHECK, H1 2026: operating income $1,254M / $10,425M = 12.0% (H1 2025: 13.1%), and that includes $106M of IEEPA tariff refunds relating to 2025 — ex-refund 11.0%. H1 is seasonally weak at GEHC (H2 2025 ran 13.7%).	13.4%	GE HealthCare 4Q/FY2025 earnings release, 8-K Ex-99 (accession 0001932393-26-000006): GAAP OPERATING INCOME, not the company's 'Adjusted EBIT'. FY2025 operating income $2,763M / revenue $20,625M = 13.40%. This line is BEFORE non-operating pension income ($288M in FY2025, a non-cash expected-return credit, deliberately excluded because the pension deficit is carried in net debt instead) and before 'other income' ($157M, of which $112M was investment revaluation gains). It INCLUDES and keeps as real costs: restructuring $120M (it has been $120M in each of the last two years — recurring, not one-off), acquisition charges $39M, spin-off costs $38M (now ~zero; leaving them in costs ~0.2pt in the base only), the ~$245M tariff hit, and $156M of acquired-intangible amortization. Management's Adjusted EBIT margin for the same year was 15.3% ($3,155M) — the ~1.9pt gap is exactly those add-backs plus the other-income line. CROSS-CHECK, H1 2026: operating income $1,254M / $10,425M = 12.0% (H1 2025: 13.1%), and that includes $106M of IEEPA tariff refunds relating to 2025 — ex-refund 11.0%. H1 is seasonally weak at GEHC (H2 2025 ran 13.7%).
Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast	6% → 4% → 4% → 4% → 4%	ESTIMATEAssumption — TickerWorth's 5-year explicit forecast
Risk-free rateUS 10Y Treasury constant maturity (FRED DGS10): 5.24% on 2026-10-01, the latest published observation. Program-wide input shared by every researched model in this run.	5.2%	US 10Y Treasury constant maturity (FRED DGS10): 5.24% on 2026-10-01, the latest published observation. Program-wide input shared by every researched model in this run.
BetaYahoo Finance / yfinance published beta (5Y monthly): Published beta 0.848, rounded to 0.85 — NOT normalized. Caveat: GEHC only began trading on 2023-01-04, so the '5Y' regression has under four years (~45 monthly points) of real history. 0.85 sits inside the range typical of large diversified medtech, so I see no stated reason to move it. Each +0.1 of beta is worth roughly -$5.5/share (beta 1.0 gives ~$56).	0.85	Yahoo Finance / yfinance published beta (5Y monthly): Published beta 0.848, rounded to 0.85 — NOT normalized. Caveat: GEHC only began trading on 2023-01-04, so the '5Y' regression has under four years (~45 monthly points) of real history. 0.85 sits inside the range typical of large diversified medtech, so I see no stated reason to move it. Each +0.1 of beta is worth roughly -$5.5/share (beta 1.0 gives ~$56).
Terminal growthESTIMATEAssumption — house default: House default 2.5% (roughly long-run nominal GDP). Reasonable for medical imaging, where ageing populations and procedure growth have historically supported mid-single-digit equipment demand; well below the 8.30% WACC. A 2.0% terminal rate takes ~$6/share off.	2.5%	ESTIMATEAssumption — house default: House default 2.5% (roughly long-run nominal GDP). Reasonable for medical imaging, where ageing populations and procedure growth have historically supported mid-single-digit equipment demand; well below the 8.30% WACC. A 2.0% terminal rate takes ~$6/share off.
Diluted sharesGE HealthCare Q2 2026 10-Q (accession 0001932393-26-000046, filed 2026-07-29): Q2 2026 weighted-average diluted shares 454M (H1 456M; FY2025 458M). Slightly conservative: GEHC bought back 4.7M shares for $300M in H1 2026 and 451.7M were outstanding at 2026-06-30 (459.5M issued less 7.8M treasury); $500M remains on the April 2025 authorization. Dilution from SBC ($130M in FY2025) is small.	454M	GE HealthCare Q2 2026 10-Q (accession 0001932393-26-000046, filed 2026-07-29): Q2 2026 weighted-average diluted shares 454M (H1 456M; FY2025 458M). Slightly conservative: GEHC bought back 4.7M shares for $300M in H1 2026 and 451.7M were outstanding at 2026-06-30 (459.5M issued less 7.8M treasury); $500M remains on the April 2025 authorization. Dilution from SBC ($130M in FY2025) is small.
Market priceDelayed quote · as of 2026-10-19 13:16 UTC	$69.57	Delayed quote · as of 2026-10-19 13:16 UTC

Change GEHC's assumptions

The discount-rate dial and the editable model

Pro

Change growth, margin and WACC yourself — Pro (7-day free trial, card required).

Start free trial Try it on Apple

What does GE HealthCare Technologies Inc. do?

What does it do?

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. It operates in the Medical Devices industry (Healthcare sector), headquartered in United States. The company employs roughly 54,000 people.

How does it make money?

The business turns $21.3B in annual revenue into profit. Out of every $100 of sales, about $15 is left as operating profit (operating margin of 15.0%), after a 40% gross margin on the products/services it sells. After all costs, taxes and interest, 9.3% of revenue becomes bottom-line net profit.

Is it financially healthy?

Financially it looks mixed: carries modest debt (0.9× equity), can just cover its short-term bills (1.3× current ratio), and is currently profitable.

Who at GEHC filed insider trades?

Recent insider filings for GE HealthCare Technologies Inc.
Date	Insider	Relationship	What happened	Value	Filing
14 Sept 2026	Grogan William K	Chief Financial Officer	Grant / award	—	Form 4 for Grogan William K (opens sec.gov in a new tab)
14 Sept 2026	Grogan William K	Chief Financial Officer	Grant / award	—	Form 4 for Grogan William K (opens sec.gov in a new tab)
3 Sept 2026	Rackliffe Philip	CEO, AIS	Shares withheld (tax)	$56,306.88	Form 4 for Rackliffe Philip (opens sec.gov in a new tab)
3 Sept 2026	O'Neill Kevin Michael	CEO, PDx	Shares withheld (tax)	$50,662.08	Form 4 for O'Neill Kevin Michael (opens sec.gov in a new tab)
3 Sept 2026	Newcomb George A.	Chief Accounting Officer	Shares withheld (tax)	$7,902.72	Form 4 for Newcomb George A. (opens sec.gov in a new tab)
3 Sept 2026	Kass-Hout Taha	Chief Technology Officer	Shares withheld (tax)	$105,981.12	Form 4 for Kass-Hout Taha (opens sec.gov in a new tab)

A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans

Common questions

What is GEHC's intrinsic value?
TickerWorth's valuation lenses put GE HealthCare Technologies Inc. (GEHC) between $40.09 and $127.43 per share, versus a market price of $69.57. They disagree too widely for us to state a single fair value, so we publish the range.
Is GEHC overvalued or undervalued?
At $69.57 the price sits inside a range too wide to call either way. We don't call GEHC overvalued or undervalued from a range this wide. This is an educational estimate, not advice.
What discount rate is used for GEHC?
A WACC of 8.3% and a terminal growth rate of 2.5%.
Is GE HealthCare Technologies stock undervalued?
TickerWorth's fair-value range for GE HealthCare Technologies Inc. (GEHC) is $40.09 – $127.43 against a market price of $69.57. Too wide to call. We publish a range here, not one number, so we do not call it over- or undervalued. This is a model estimate, not investment advice.
GE HealthCare Technologies (GEHC) DCF valuation and fair value
Our fair-value range for GE HealthCare Technologies Inc. (GEHC) is $40.09 – $127.43, built on a 8.3% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into GE HealthCare Technologies stock?
Today's price implies revenue growth of 4.5% a year for 5 years; our model assumes 4.3% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $69.57. A model estimate, not investment advice.
GE HealthCare Technologies (GEHC) insider trading
The most recent insider filing (SEC Form 4) for GE HealthCare Technologies Inc. (GEHC): Grogan William K, Chief Financial Officer, grant / award on 2026-09-14. The latest filings are listed on this page. A disclosure, not a signal to trade.